Prognostic Value of Quantitative-PCR versus Serology for Detection of CMV in Pre- and Post- Transplantation

Biology Department, Faculty of Science- KAAU, Jeddah, Kingdom of Saudi Arabia.
The Egyptian journal of immunology / Egyptian Association of Immunologists 01/2010; Vol. 17:Page: 41-48.

ABSTRACT Two hundred-twenty six pre- and post- kidney transplantation patients were screened for CMV. They were categorized into three groups I: Eighty-five dialysis patients suffering from chronic renal failure, II: Sixty –two end stage renal disease patients prepared for transplantation, and III: Seventy-nine post-kidney transplant patients under immunosuppressive and cytotoxic therapy. The last group was subdivided according to
clinical presentation into asymptomatic, mild, and invasive CMV disease subgroups. A control group comprised of fifty-two apparently healthy kidney and blood donors were also included. Serum and plasma samples were utilized for detection of anti-CMV antibodies by EIA, and determination of CMV viral load by quantitative -PCR respectively. QT-PCR results revealed high viral load; (4000-10.000 copy/ml) in 16(100%) kidney recipient with invasive CMV disease, While only 4 (25%) of them were positive for IgM anti-CMV. Another ten patients with symptoms of CMV syndrome were found CMV-PCR positive with low viral load (436-3070 copy/ml) and all were negative for IgM anti-CMV. On the other hand, no CMV viral load was detectable among end-stage renal disease patients, although 6/62(9.7%) were positive for IgM anti-CMV. All
subjects were positive for IgG anti-CMV. It is concluded that QT-PCR rather than serology should be used for monitoring of CMV infection in pre- and post-transplantation patient.

Download full-text


Available from: Sanaa Al-Attas, Jun 23, 2015
1 Follower
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Plasma PCR for human cytomegalovirus (CMV) DNA was compared with bronchoalveolar lavage (BAL) fluid culture as an indicator for disseminated CMV infection. Thirteen (32.5%) of 40 consecutive bone marrow transplant (BMT) recipients were BAL fluid culture positive for CMV on day 35 post-BMT, and 9 (69%) of the 13 had positive plasma PCRs between days 28 and 49. Of the 27 with negative BAL fluid cultures, 2 (7%) had positive plasma PCRs (P < 0.001). Plasma CMV DNA in BMT recipients is a useful clinical marker for serious infection.
    Journal of Clinical Microbiology 10/1994; 32(9):2266-9. · 4.23 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Eight laboratory assays, viz., the pp65 direct antigenemia test, a quantitative cytomegalovirus (CMV)-specific immunoglobulin G (IgG) assay (Biomerieux VIDAS), a CMV-specific IgM assay (Biomerieux VIDAS), the Hybrid Capture system (Murex), an in-house PCR with plasma (P-PCR) and leukocytes (L-PCR), and a commercial PCR (Roche AMPLICOR) with plasma (P-AMP) and leukocytes (L-AMP), were compared for their abilities to predict CMV disease before the onset of illness in a prospective study of 37 renal transplant recipients. By using an expanded criterion for active infection (two or more of the markers positive) and a clinical definition of disease, 22 (59%) patients were identified as having active CMV infection and 13 (35%) were identified as having CMV disease. Of the 13 CMV-seronegative recipients who received seropositive kidneys (R- group), 8 had active infection and disease. All assays were 100% specific and 100% predictive of CMV disease in the R- group. The leukocyte PCRs (L-PCR and L-AMP) were the most sensitive assays, had positive results an average of between 8 and 13 days before the onset of illness, and were the assays of choice. The performance of the assays was less satisfactory for the 24 patients who were CMV seropositive before transplantation (R+ group). A negative result was more useful for this group. Overall, P-AMP had the best results, and it could be the assay of choice for monitoring R+ patients. The non-PCR-based methods generally had high specificities but often gave late positive results and were not sensitive enough for use as prediction tools for either group of patients.
    Journal of Clinical Microbiology 10/1998; 36(9):2681-5. · 4.23 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Human cytomegalovirus (CMV), a ubiquitous member of the herpesvirus family, is an important human pathogen. Infections are usually asymptomatic but can be associated with a wide spectrum of diseases, particularly in immunocompromised persons. Primary infection during pregnancy may result in congenital infection leading to severe damage of the fetus. Intrauterine primary infections are second only to Down's syndrome as a known cause of mental retardation. CMV infection in transplant recipients may cause different clinical syndromes in different groups of patients, and the severity of the infection parallels the degree of immunosuppression.As infections are either asymptomatic or accompanied by symptoms that are not specific to CMV (such as fever and leukopenia), laboratory techniques are the sole means of diagnosing CMV infection. Diagnosis of CMV infection can be made directly by demonstration of the virus or virus components in clinical samples or indirectly through serology. Part I of this article reviews infections in immunocompromised patients and the various approaches to monitoring and laboratory diagnosis of CMV infection.
    Clinical Microbiology Newsletter 01/2010; DOI:10.1016/j.clinmicnews.2009.12.001